Abstract
Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.
Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.
Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes.
Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
Keywords: Congenital anomalies, drugs, glaucoma, pregnancy, prenatal diagnosis, Teratology Information Service (TIS).
Current Drug Safety
Title:Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series
Volume: 13 Issue: 1
Author(s): Marcella Pellegrino*, Luisa D`Oria, Carmen De Luca, Giacomina Chiaradia, Angelo Licameli, Caterina Neri, Marta Nucci, Daniela Visconti, Alessandro Caruso and Marco De Santis
Affiliation:
- Teratology Information Service, Department of Obstetrics and Gynecology, Fetal Diagnosis and Therapy Unit, Catholic University of Sacred Heart, Policlinico A. Gemelli Hospital, Rome,Italy
Keywords: Congenital anomalies, drugs, glaucoma, pregnancy, prenatal diagnosis, Teratology Information Service (TIS).
Abstract: Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.
Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.
Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes.
Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
Export Options
About this article
Cite this article as:
Pellegrino Marcella *, D`Oria Luisa , De Luca Carmen , Chiaradia Giacomina , Licameli Angelo, Neri Caterina , Nucci Marta, Visconti Daniela , Caruso Alessandro and De Santis Marco , Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886312666171030125804
DOI https://dx.doi.org/10.2174/1574886312666171030125804 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Vaccination Against High Blood Pressure
Current Pharmaceutical Design Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neuroprotective Effects of Estrogens: Cross-Talk Between Estrogen and Intracellular Insulin Signalling
Infectious Disorders - Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design Cardiovascular Effects of Metabolic Surgery on Type 2 Diabetes
Current Cardiology Reviews Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety